Oxford Nanopore Technologies (ONT) Bank of America Global Healthcare Conference 2024 summary

Financial performance and outlook

• Achieved £84.1 million in first-half revenue, representing 12.5% underlying growth, at the top end of guidance.

• Gross margin reached 58.8%, beating the 57% guidance, with a medium-term target of 62% by 2027.

• Outlined a path to break even by 2027 and positive cash flow in 2028.

• Revenue growth supported by large contracts (PRECISE, NIHR) and increased device utilization.

• Second-half growth confidence driven by improved sales force efficiency and a robust opportunity funnel.

Market and product dynamics

• Double-digit growth in China despite market headwinds, driven by strong service lab adoption.

• 70% of business from research markets, with growing opportunities in applied, industrial, and biopharma segments.

• Plasmid sequencing and telomere-to-telomere workflows gaining traction, especially in APAC.

• New Q-Line platform launched, offering locked-down software for clinical and pharma markets, with strong early demand.

• Product mix and regional adoption trends influence growth and margin outlook.

Competitive landscape and technology

• Gaining market share in a tough environment due to lower device price points and flexible purchasing models.

• Technology improvements, especially in accuracy and workflow variety, are driving customer adoption.

• Not directly competing with short-read players; focus is on comprehensive data and methylation analysis.

• Large contracts like PRECISE serve as validation and boost recognition, especially in APAC and EMEA.

• Sensing platform approach enables entry into new markets beyond DNA sequencing.